Clinical Trial Update: Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the efficacy and safety of extended-release hydromorphone (Exalgo) in patients with neuropathic pain; results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Pain

Drugs mentioned

• Exalgo (extended-release hydromorphone) (hydromorphone)

Snippet

Sponsor: International Clinical Research Institute | Conditions: Neuropathic Pain | Phase 4 | Status: COMPLETED | Results posted: 2012-06-20